Phaseline

Targets › ITGA11

ITGA11 (Integrin alpha-11): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Integrin alpha-11/beta-1 is a receptor for collagen. (UniProt, Q9UKX5)

Open in Phaseline: the race on ITGA11, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Peter MacCallum Cancer Centre, AustraliaRadium-223
Bone-targeting alpha-emitting radiopharmaceutical targeting bone metastases
ITGA11Phase 1Metastatic Castration-resistant Prostate CancerDec 2026

Conditions

Metastatic Castration-resistant Prostate Cancer (1)

Modalities

small molecule (1)

Companies

Peter MacCallum Cancer Centre, Australia (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.